N-[[1-[(2R,3R,4S,5R)-5-[2-[dimethyl(methylidene)-lambda5-phosphanyl]ethyl]-3,4-dihydroxyoxolan-2-yl]-2,4-dioxopyrimidin-5-yl]methyl]-N-(4,4-dimethyl-2-oxopentyl)-2,2,2-trifluoroacetamide

• 分子结构分类: 有机化合物 - 核苷、核苷酸和类似物 - 5'-脱氧核糖核苷
• 英文名称: N-[[1-[(2R,3R,4S,5R)-5-[2-[dimethyl(methylidene)-lambda5-phosphanyl]ethyl]-3,4-dihydroxyoxolan-2-yl]-2,4-dioxopyrimidin-5-yl]methyl]-N-(4,4-dimethyl-2-oxopentyl)-2,2,2-trifluoroacetamide
• 英文别名: N-[[1-[(2R,3R,4S,5R)-5-[2-[dimethyl(methylidene)-λ5-phosphanyl]ethyl]-3,4-dihydroxyoxolan-2-yl]-2,4-dioxopyrimidin-5-yl]methyl]-N-(4,4-dimethyl-2-oxopentyl)-2,2,2-trifluoroacetamide
• 化学式: C₂₃H₃₅F₃N₃O₇P
• 分子量: 553.5
• InChiKey: MXKPHTMUOGBCNL-YWTNHNAXSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.3
• 重原子数：
  37
• 可旋转键数：
  10
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.7
• 拓扑面积：
  137
• 氢给体数：
  3
• 氢受体数：
  10

文献信息

• MODIFIED POLYNUCLEOTIDES ENCODING CITED4
  申请人：MODERNA THERAPEUTICS, INC.

  公开号：US20140186432A1

  公开（公告）日：2014-07-03

  The invention relates to compositions and methods for the preparation, manufacture and therapeutic use of polynucleotides, primary transcripts and mmRNA molecules.
• HETEROLOGOUS UNTRANSLATED REGIONS FOR MRNA
  申请人：MODERNA THERAPEUTICS, INC.

  公开号：US20160022840A1

  公开（公告）日：2016-01-28

  The invention relates to compositions and methods for the manufacture and optimization of modified mRNA molecules via optimization of their terminal architecture.
• MODIFIED NUCLEIC ACIDS, AND ACUTE CARE USES THEREOF
  申请人：Moderna Therapeutics, Inc.

  公开号：US20160256573A1

  公开（公告）日：2016-09-08

  The invention provides compositions and methods for effecting wound healing in a mammal, where the compositions include therapeutic mRNA which incorporate modified nucleosides and nucleotides.
• US9114113B2
  申请人：——

  公开号：US9114113B2

  公开（公告）日：2015-08-25